Breast Cancer Trial, Recruiting NCT06694519 Sponsor: SERGIO MONTERO NAVARRO Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06694519
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women of legal adult age who have a history of breast cancer and are experiencing pelvic floor problems, measured by a specific questionnaire (called the PFDI-20) with a score of 100 or higher
  • Women who have survived Stage 1 or Stage 2 breast cancer
  • Women who were formally discharged from cancer treatment more than one year ago
  • Women who have not been diagnosed with any other type of cancer

Who may not be able to join:

  • Women who have had pelvic floor muscle training or radiofrequency treatment in the last 12 months
  • Women who have used vaginal oestrogen products in the last 6 months
  • Women who have been on systemic hormone therapy (hormones taken by mouth, injection, or patch) in the last 6 months
  • Women who have had laser therapy in the last 6 months
  • Women whose pelvic floor muscles show no ability to contract, as assessed by a standard clinical scale (the Modified Oxford Scale)
  • Women who use a pacemaker
  • Women with uncontrolled heart or metabolic conditions, cognitive difficulties, nerve-related conditions (affecting either the brain/spinal cord or the peripheral nerves), previous surgery in the pelvic area, skin problems or open wounds in the treatment area, or a current urinary tract or vaginal infection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: ANA LOZANO, MsC, CARDENAL HERRERA - CEU; CEU UNIVERSITIES

Phone: +34 965426486

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
SERGIO MONTERO NAVARRO
Registry
ClinicalTrials.gov
Start date
30 January 2025
Est. completion
30 December 2025

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

PFDI-20 questionnaire (300 points)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov